Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3279 - Impact of prior immune checkpoint inhibitors on haematological toxicity in Phase I patients receiving chemotherapy


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Supportive Care and Symptom Management;  Immunotherapy


Alvaro Ingles Garces


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


A.H. Ingles Garces1, J.E. Ang1, M. Ameratunga1, M. Chenard-Poirier1, D. Dolling2, R. Sundar1, S. Kaye1, J. de Bono1, U. Banerji1, J. Lopez1

Author affiliations

  • 1 Drug Development Unit, The Royal Marsden NHS Foundation Trust, SM2 5PT - London/GB
  • 2 Oncology, Institute of Cancer Research Royal Marsden Hospital, SM2 5PT - Sutton/GB


Abstract 3279


Immune checkpoint inhibitors (ICI) are used increasingly and earlier to treat multiple cancers. Although rates of on-treatment myelotoxicity are low, there are no published data on the long-term effects of ICI. This is a pilot study to evaluate the impact of prior ICI exposure on chemotherapy-related myelotoxicity in patients in the Phase I setting.


We conducted a retrospective chart review of patients treated between 2012 and 2016 in the Drug Development Unit, The Royal Marsden Hospital. Multivariate logistic regression (including number of previous treatment lines and type of chemotherapy) was used to assess possible relationships between G3/4 neutropenia or thrombocytopenia and previous treatment with immunotherapy in patients receiving combination chemotherapy and targeted agents.


We identified 99 patients (median age 62 years [range 34-79]; chemotherapy partners: cisplatin, carboplatin and paclitaxel). Fourteen patients (14%) received prior immunotherapy (PI) and 85 (86%) had no prior immunotherapy (NPI). Patient characteristics, including baseline full blood count, previous pelvic radiotherapy, sites of metastasis and serum albumin, were comparable between the 2 groups, apart from number of previous treatment lines, which was lower in the PI patients (median 1.5 vs 2, p = 0.003). The odds of G4 neutropenia were higher in the PI group (OR = 7.1, 95% CI = 1.7-29.6, p = 0.007). PI was associated with significantly increased odds of G3/4 thrombocytopenia (OR = 14.4, 95% CI = 2.7-77.4, p = 0.002) on chemotherapy. In multivariate analysis, incorporating lines of prior chemotherapy (OR 1.3, 95% CI = 1.0-1.5, p = 0.037) and type of chemotherapy (carboplatin vs others: OR 2.3, 95% CI = 0.9-6.2, p = 0.094), the odds of developing G3/4 myelotoxicity were significantly higher in PI patients (OR 4.3, 95% CI: 1.3-14.4, p = 0.02).


In our small cohort, previous treatment with immunotherapy was associated with the development of G3/4 myelotoxicity, especially thrombocytopenia, on subsequent chemotherapy. These preliminary data require further prospective validation but may impact on decision making regarding optimal sequencing of systemic therapy.

Clinical trial identification

Legal entity responsible for the study

The Royal Marsden Hospital NHS Foundation Trust




J. de Bono: Consulting or advisory role: Astex, AstraZeneca, Genentech, Genmab, GSK, Merck, Pfizer, Sanofix Research Funding: AstraZeneca, Genentech, GSK, Sanofi, Janssen. U. Banerji: Receipt of grants/research supports: AstraZeneca, Chugai, Onyx, BTG Receipt of honoraria or consultation fees: Astex, Karus Therapeutics, Novartis, Vernalis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.